SpliSense

Private

JerusalemHealthcare & Life Scienceshttps://splisense.com/

Last Round

Grant

Jun 16, 2026

Total Funding Raised

$38.4M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

SpliSense is a biotechnology company that develops innovative RNA-based therapies using antisense oligonucleotides to treat cystic fibrosis and other genetic pulmonary diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

Antisense OligonucleotidesASOcystic fibrosis treatmentRNA therapeuticsmRNA-alteringinhaled therapiessplicing modulationpulmonary diseasesgenetic medicineCFTR restorationorphan drugIdiopathic Pulmonary FibrosisIPFclinical-stage biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

SpliSense Comps

Public and private peers based on sector, stage, and business model.

SpliSense comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

SpliSense Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Grant	Jun 16, 2026
Grant	Apr 3, 2024
Series B	May 13, 2021

View all Funding Rounds

Key People

Founding team and executive leadership

Gili Hart

Chief Executive Officer

Executive Team

SpliSense Investors

Notable investors and investment history

SpliSense investors
Investor	Rounds
Israel Biotech Fund	Series B, Grant
OrbiMed	Grant, Series B
Integra Holdings	Series B, Series A, Grant
Cystic Fibrosis Foundation	Series B, Grant

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Jun 16, 2026
Raised $13M with Cystic Fibrosis Foundation leading.

View all signals

SpliSense Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

SpliSense Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about SpliSense's valuation, stock price, and market status.

Firmographic Details

HeadquartersJerusalem

Employee Range16

Year Founded2016

Last FundingJun 16, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.